

NEONATAL Medication Monograph

OSELTAMIVIR

This document should be read in conjunction with this **DISCLAIMER**

Restricted: Requires Neonatologist or Microbiologist review within 24 hours of initiation

Antiviral therapy should be commenced within 48 hours of symptoms or contact with an infected person

Presentation	Oral Powder for Suspension: 6mg/mL Oral Capsule: 75mg				
Description	Oseltamivir is a neuraminidase inhibitor. It reduces influenza virus replication by inhibiting the viral surface enzyme neuraminidase thereby preventing release of new virus from cells				
Indications	Treatment of confirmed or suspected influenza virus				
Contraindications	Contraindicated in patients with a previous hypersensitivity reaction to oseltamivir or other neuraminidase inhibitor				
Precautions	Hereditary fructose intolerance as oseltamivir powder for oral suspension (Tamiflu®) contains 0.9g of sorbitol for every 30mg of oseltamivir				
Dosage	Oral: Usual Duration of treatment is 5 Days <u>Note:</u> Longer treatment may be necessary for patients whose illness is prolonged, critically ill patients with respiratory failure or immunosuppressed people as per microbiology				
		Gestational age	Dose	Frequency	
		<38 weeks	1 mg/kg	Every 12 hours	
		38-40 weeks	1.5 mg/kg	Every 12 hours	
		>40 weeks	3 mg/kg	Every 12 hours	
			1	1	1

Dosage Adjustment	Dose adjustment may be required in renal impairment. Contact Microbiology			
Adverse Reactions	Common: nausea, vomiting (usually for first 1–2 days), mild rash, transient rise in transaminases			
	Serious: Anaphylaxis, severe skin reactions			
Preparation	Oral Powder for Suspension Add 55 mL of water to bottle containing oseltamivir powder for suspension Final concentration is 6mg/mL Use commercial solution if available If solution not available – prepare the following solution using 75mg oseltamivir capsules • Open ONE oseltamivir capsule (75mg) and disperse the contents in 12.5mL of water. • Shake or stir until an even dispersion is formed (≈ 2 minutes) and then measure the dose immediately. • Concentration is 75mg/12.5mL = 6mg/mL • Discard any unused solution			
Administration	Oral: May be given with or without food. Tolerability may be improved with food To avoid confusion with dosing, the supplied Tamiflu® oral syringe should <u>not</u> be used.			
Monitoring	Closely monitor patients with influenza for neurologic symptoms and symptom improvement			
Storage	The Commercial reconstituted suspension does NOT require refrigeration and should be discarded 10 days after reconstitution. Discard any unused dispersed capsule solution immediately.			
Notes	The osmolality of a dispersed capsule is 75 mOsm/kg. The osmolality of the suspension will be greater than this, and is suitable for infants on full feeds.			

References	Truven Health Analytics. Oseltamivir. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2020 [cited 2020 Apr 06]. Available from: <u>https://neofax.micromedexsolutions.com/</u>
	Australian Medicines Handbook. Oseltamivir. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Apr 06]. Available from: <u>https://amhonline.amh.net.au/</u>
	MIMS Australia. Tamiflu Powder for oral suspension, Capsules. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2020 [cited 2020 Apr 06]. Available from: <u>https://www.mimsonline.com.au</u>

Keywords:	Oseltamivir, Tamiflu, influenza, flu					
Publishing:	Intranet Internet					
Document owner:	Head of Department - Neonatology					
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate					
Date first issued:	October 2013	Version:	3.0			
Last reviewed:	April 2020	Next review date:	April 2023			
Endorsed by:	Neonatal Directorate Management Group	Date:	April 2020			
Standards Applicable:	NSQHS Standards: 1 ⁽²⁾ Governance, 3 ⁽²⁾ Infection Control, 4 ⁽²⁾ Medication Safety, 8 ⁽²⁾ Acute Deterioration					
Printed or personally saved electronic copies of this document are considered uncontrolled.						
Access the current version from the WNHS website.						
For any enquiries relating to this guideline, please email <u>KEMH.PharmacyAdmin@health.wa.gov.au</u>						
© Dopartment of Health Western Australia 2010						

© Department of Health Western Australia 2019